Founded in 1993
  Year: 1997 | Volume: 5 | Issue: 4 | Pages: 203-204
  Actual Problem
  ALTERNATING CARBOPLATINE/ETOPOSIDE AND EPIRUBICINE/IFOSFAMIDE PLUS THORACIC IRRADIATION IN SMALL CELL LUNG CANCER
Antonio CAPIZZELLO, Irene TERZI, Evi KALAITZIDOU, Leonida PAPADOPOULOS
  DOI:
  Abstract:
  The purpose of the study was to investigate the effectiveness of combined chemotherapy and radiotherapy in patients who were in a stage of limited disease in small cell lung cancer. After the diagnosis, from December 1991 to April 1993, a total of 17 patients suffering from small cell lung cancer were subjected to 12- week chemotherapy: a course of Carboplatine 180mg/m2 and Etoposide 75mg/m2 at the 1st, 3rd, 5th, 7th,9th and 11th week and a course of Epirubicin 37.5 mg/m2 and Ifosfamide 2.5 g/m2 at the 2nd, 4th, 6th, 8th,10th and 12th week. After chemotherapy, 15 patients received radiotherapy. Radiation therapy consisted of 46 Gy/23 fr (195 cGy/fr) at mediastinum and the primary tumor, followed by the "boost" 10Gy (200 cGy/fr) directed to the residual disease. After thoracic irradiation all patients were subjected to the prophylactic cranial irradiation with a dose of 24 Gy/12 fr (200 cGy/fr). The treatment was well tolerated. Eight patients achieved complete response in a median time of 2.25 months from the beginning of the therapy (range 12 days - 5 months). The median duration of complete response was 3 months (1.5 - 5 months) for four patients who had a local relapse or a metastasis. The median survival for eight complete responders was 16.55 months (range 6 - 55.6 + months) and for the partial responders was 7.3 months (range 3,7 - 10,23 months). In conclusion this schedule of combined chemotherapy and radiotherapy has proved to be associated with acceptable toxicity and it was well tolerated. The results showed an efficacy on local control but did not exclude the possibility of a minor survival advantage. The scheme appeared to be substantially beneficial in terms of toxicity, adverse effects on daily life and well being, but not in terms of time of progression or rates of survival.
  Key words: Small cell lung cancer; Chemotherapy; Radiotherapy; Limited disease; Prophylactic cranial irradiation; Carboplatine
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:
 

  Related articles in AoO:
 
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder and owner: Oncology Institute of Vojvodina, Serbia
Publisher: Oncology Institute of Vojvodina
Co-publisher: Faculty of Medicine, University of Novi Sad
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520